U.S., Oct. 10 -- ClinicalTrials.gov registry received information related to the study (NCT07214064) titled 'Venetoclax- Augmented Treosulfan-Based Reduced Intensity Conditioning Before Allogeneic Stem Cell Transplantation' on Oct. 02.
Brief Summary: Safety and Feasibility of a Venetoclax- Augmented Treosulfan-Based Reduced Intensity Conditioning Before Allogeneic Stem Cell Transplantation in AML, MDS/AML and Higher Risk MDS
Study Start Date: Jan., 2026
Study Type: INTERVENTIONAL
Condition:
AML (Acute Myeloid Leukemia)
MDS/AML
MDS (Myelodysplastic Syndrome)
Intervention:
DRUG: RIC regimen
Venetoclax (Venclyxto(R)): 400 mg abs./d day -8 to -2, Fludarabine 30 mg/m2 BSA day -6 to day -2, Treosulfan 10 g/m2 BSA day -4 to day -2
Recruit...